Atipamezole

Atipamezole
Clinical data
Trade names	Antisedan, others
AHFS/Drugs.com	Veterinary Use; Veterinary Use;
License data	US DailyMed: Atipamezole;
Routes of; administration	Intramuscular
Drug class	Reversal agent
ATCvet code	QV03AB90 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Metabolism	Liver
Onset of action	Less than 3 min.
Elimination half-life	2.6 hours (dogs)
Excretion	Kidney
Identifiers
	IUPAC name 4-(2-Ethyl-1,3-dihydroinden-2-yl)-3H-imidazole;
CAS Number	104054-27-5 ;
PubChem CID	71310;
DrugBank	DB11481 ;
ChemSpider	64427 ;
UNII	03N9U5JAF6;
KEGG	D03002 ;
CompTox Dashboard (EPA)	DTXSID2049135 ;
Chemical and physical data
Formula	C14H16N2
Molar mass	212.296 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [nH]1cc(nc1)C3(Cc2c(cccc2)C3)CC;
	InChI InChI=1S/C14H16N2/c1-2-14(13-9-15-10-16-13)7-11-5-3-4-6-12(11)8-14/h3-6,9-10H,2,7-8H2,1H3,(H,15,16) ; Key:HSWPZIDYAHLZDD-UHFFFAOYSA-N ;
	(what is this?) (verify)

Atipamezole, sold under the brand name Antisedan among others, is a synthetic α₂ adrenergic receptor antagonist used for the reversal of the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs. Its reversal effect works by competing with the sedative for α₂-adrenergic receptors and displacing them. It is mainly used in veterinary medicine, and while it is only licensed for dogs and for intramuscular use, it has been used intravenously, as well as in cats and other animals (intravenous use in cats and dogs is not recommended due to the potential for cardiovascular collapse. This occurs due to profound hypotension caused by reversal of the alpha 1 effects while the reflex bradycardia is still in effect.). There is a low rate of side effects, largely due to atipamezole's high specificity for the α₂-adrenergic receptor. Atipamezole has a very quick onset, usually waking an animal up within 5 to 10 minutes.

It was originally released in 1996. It is available in as a generic medication.